Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Z Orlowski

Showing results (1-10 of 303) with videos related to

Pageof 31
Sort By:
Seminars in Oncology|October 19, 2013
Novel agents for multiple myeloma to overcome resistance in phase III clinical trialsRobert Z Orlowski
Expert Review of Anticancer Therapy|April 2, 2004
Bortezomib and its role in the management of patients with multiple myelomaRobert Z Orlowski
Hematology. American Society of Hematology. Education Program|November 25, 2006
Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantationRobert Z Orlowski
Methods in Molecular Biology (Clifton, N.J.)|May 27, 2005
Proteasome inhibitors in cancer therapyRobert Z Orlowski
Oncology (Williston Park, N.Y.)|September 5, 2014
The future of proteasome inhibitors in relapsed/refractory multiple myelomaRobert Z Orlowski
Cancer Cell|September 14, 2013
Why proteasome inhibitors cannot ERADicate multiple myelomaRobert Z Orlowski
Hematology. American Society of Hematology. Education Program|November 24, 2005
The ubiquitin proteasome pathway from bench to bedsideRobert Z Orlowski
Journal of Managed Care & Specialty Pharmacy|April 26, 2018
Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple MyelomaRobert Z Orlowski
Journal of the National Comprehensive Cancer Network : JNCCN|October 2, 2009
Bortezomib in combination with other therapies for the treatment of multiple myelomaRobert Z Orlowski
Leukemia & Lymphoma|April 6, 2004
Successful pregnancy after cladribine therapy for hairy cell leukemiaRobert Z Orlowski
Pageof 31

Showing results (1-10 of 303) with videos related to

Sort By:
Pageof 31
Seminars in Oncology|October 19, 2013
Novel agents for multiple myeloma to overcome resistance in phase III clinical trialsRobert Z Orlowski
Expert Review of Anticancer Therapy|April 2, 2004
Bortezomib and its role in the management of patients with multiple myelomaRobert Z Orlowski
Hematology. American Society of Hematology. Education Program|November 25, 2006
Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantationRobert Z Orlowski
Methods in Molecular Biology (Clifton, N.J.)|May 27, 2005
Proteasome inhibitors in cancer therapyRobert Z Orlowski
Oncology (Williston Park, N.Y.)|September 5, 2014
The future of proteasome inhibitors in relapsed/refractory multiple myelomaRobert Z Orlowski
Cancer Cell|September 14, 2013
Why proteasome inhibitors cannot ERADicate multiple myelomaRobert Z Orlowski
Hematology. American Society of Hematology. Education Program|November 24, 2005
The ubiquitin proteasome pathway from bench to bedsideRobert Z Orlowski
Journal of Managed Care & Specialty Pharmacy|April 26, 2018
Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple MyelomaRobert Z Orlowski
Journal of the National Comprehensive Cancer Network : JNCCN|October 2, 2009
Bortezomib in combination with other therapies for the treatment of multiple myelomaRobert Z Orlowski
Leukemia & Lymphoma|April 6, 2004
Successful pregnancy after cladribine therapy for hairy cell leukemiaRobert Z Orlowski
Pageof 31